Key Takeaways
- Record revenue, margin investment: Revenue hit an all-time high of INR321 crores, but EBITDA margin fell to 9.2% as the company deliberately built SG&A capacity ahead of scale.
- Order book lumpy but pipeline healthy: The order book dipped to ~INR2,300 crores from a peak of 2,550 crores because large strategic programs do not award on a steady quarterly cadence; management expects growth to resume as several large deals sit in advanced stages.
- Cash flow consumed by working capital: INR34 crores of free cash was consumed in Q3 as customer advances dropped ~15 days; full-year break-even is the aspiration but generating INR230 crores in one quarter will be difficult.
- Defence concentration is the margin story: A single large defence customer continues to drive bulk of sales at lower margins; mix shift toward aero, medical and industrial is the path to 11%-12% EBITDA, but that shift is gradual.
- What to watch next quarter: Whether the order book stabilizes around INR2,000 crores as promised, whether Q4 EBITDA margin hits the 10%-10.5% expectation, and whether an LOI on M&A actually closes.
Revenue & Profitability
- Top-line driver: Aerospace and defence segments powered the record quarter, with customers placing more confidence in Cyient DLM's capabilities.
- PAT surge: Profit after tax grew 222.6% year-on-year, boosted by other income alongside volume growth.
- Operating leverage gap: 50% revenue growth translated to only 30% EBITDA growth because of conscious SG&A investment to build an organization that can serve INR30-50 crore revenue in the long term.
- Employee cost step-up: RSU costs began amortizing this quarter (performance and tenure conditions), and the full-quarter impact of leadership hires also landed.
- IPO expenses: INR41 crores in issue expenses are one-time, set off directly against equity under accounting standards, and do not flow through the P&L.
- Gross margin question deflected: Management declined to discuss gross margin, stating the company does not report it, and redirected analysis to EBITDA.
Shrinivas Kulkarni: "The 50% growth in the revenue is translating to a 30% growth in the EBITDA. That's largely because of investing in SG&A. I think that is where the bulk of the investments have been made. And this is a very conscious call to build an organization which will cater to 30 crore to, in the short term to about 50 crore in the long term."
Order Book & Pipeline
- Order book decline: The book fell from a peak of INR2,550 crores to about INR2,300 crores, driven by the lumpy nature of order wins and delayed conversion of large strategic programs that do not award on a monthly or quarterly basis.
- New wins: $10 million in new awards from an OI perspective, spread over three to four years, primarily defence with an existing client seeing increased demand.
- Two new logos added: More expected to be announced in the coming quarter.
- Pipeline confidence: Management has confidence to maintain the order book around INR2,000 crores for the next few quarters, subject to pipeline conversion, with consistent end-market demand maintaining.
- Pipeline quantification declined: Management would not provide a ballpark figure for the order pipeline, stating "that's not a number we declare out."
- BAE and Safran specifics withheld: When asked what kind of work is planned for the two new logos announced last quarter, management declined to provide specifics, only saying it falls under standard air and defence EMS offerings.
Anthony Montalbano: "A lot of our programs are with larger clients on these bigger, more strategic programs. And the award of those is not a continual monthly or even quarterly type of business award."
Margins & Cost Structure
- EBITDA margin walk: At 9.2%, down 45 bps YoY and 132 bps vs the previous year, driven entirely by planned SG&A investments including onboarding of senior executives.
- SG&A peak claim: Management stated SG&A expenses have peaked; with higher revenue expected in Q4, the company expects to reach double-digit margins and stay there, with no significant further SG&A investment planned.
- Q4 margin expectation: Management expects around 10% to 10.5% EBITDA margin in Q4, clarifying this is an expectation, not formal guidance.
- Medium-term trajectory: Margins will probably stay around 10% for some time, then inch toward 11%-12% as business mix changes and scale benefits accrue.
- Interest cost: Interest expense will drop substantially in Q4 because remaining working capital loans are being paid off; the repayment happened toward quarter-end so the Q3 impact was marginal.
- Shipping freight: A marginal increase of 5%-10%, not the 30%-40% some feared; no impact from Red Sea disruptions on export dispatches.
Shrinivas Kulkarni: "I think we will get to 11%-12% very quickly. It will probably stay around the 10% for some time. As we find other opportunities where the mix of the business changes and then we get the benefits of the scale, we will start inching towards 11%-12%."
Working Capital & Cash Flow
- Free cash flow consumption: INR34 crores consumed in Q3 because the customer advance base dropped by about 15 days, marginally increasing net working capital.
- Full-year cash flow: Management aspires to break even on cash flow from operations for the full year but may be a little shy because INR230 crores was consumed in the first nine months; generating that level of cash in one quarter will be difficult, though there is a healthy line of sight to get very close.
- Inventory days: Reduced to 137 days; the goal is 120 days in the short term (expected substantially in Q4) and 90 days in the medium term.
- DSO improvement: Expected to go down in Q4 as December overdues are collected; revenue phasing earlier in the quarter provides opportunity to collect cash within the same quarter.
- IPO proceeds: Used to repay external loans and consume about INR80 crores toward working capital, as stated in the RHP with no deviations.
Shrinivas Kulkarni: "No, on a full-year basis, we aspire to break-even, but we might be a little bit shy of that because we have consumed almost INR230 crores in the first nine months. So, to generate that level of cash in one quarter will be difficult."
Segments & Mix Shift
- Box build share decline: Box build as a percentage of revenue fell YoY because last year had medical customers like Molbio with significant box build revenue that has now reduced; this is not a deliberate strategy, and the margin profile remains the same between segments.
- Defence concentration: The low-margin business with the key defence customer will continue into next year; other parts of the business are growing, so there will be a gradual change in mix.
- Segment outlook: A&D will continue to play a significant part; as the next fiscal year executes, the defence piece may start to come down a little as a share of overall mix; aero will remain very significant; medical and industrial will make up a greater share.
- Medical pipeline: The pipeline in medical is translating into orders that will be closed in the coming quarters.
- Parent-subsidiary boundary: Wherever there is manufacturing, the whole deal is owned by Cyient DLM; if Cyient needs to support on engineering and design elements, Cyient will support.
Krishna Bodanapu: "the overarching principle would follow is wherever there is manufacturing, the whole deal is owned by Cyient DLM. And if Cyient needs to support on the engineering and the design elements, Cyient will support."
Capacity, Facilities & Leadership
- Capacity utilization: Mysore is at peak capacity, prompting expansion plans; Hyderabad is still low on utilization (it is an SEZ with its own challenges for suddenly changing capacity); overall capacity utilization is close to around 50%.
- New Bangalore facility: A 36,000-square-foot precision machining facility was inaugurated, offering high-value vertically integrated services for aero and defence clients.
- New Mysore facility: A leased premise (a software park being converted) has been identified to support growth in medical and industrial sectors; it will be ready only in the next financial year, with minimal capex of about a couple of million dollars.
- Leadership hires: Kaushal Jadia appointed as CTO with 30 years of experience, focused on design-led manufacturing and expanding the defence business; Mac Vyas appointed to head Supply Chain Management, also with 30 years of experience.
- Supply chain optimization: In progress through automation, with the new leader now on board.
Anthony Montalbano: "This is a key addition to our leadership team and he is really a differentiator in the markets as far as having the ability to truly bring design-led solutions from a manufacturing perspective."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Order book maintenance | Maintain order book around INR2,000 crores, subject to pipeline conversion | Next few quarters |
| Q4 EBITDA margin | Reach around 10% to 10.5% (expectation, not guidance) | Q4 FY24 |
| Medium-term EBITDA margin | Inch toward 11%-12% as mix changes and scale benefits accrue | No fixed date |
| Inventory days | Reduce to ~120 days | Q4 FY24 |
| Free cash flow | Positive free cash flow expected | Q4 FY24 |
| Interest cost | Substantial reduction as remaining working capital loans are paid off | Q4 FY24 |
| SG&A investment | No significant further SG&A investment expected; expenses have peaked | From Q4 FY24 onward |
| New Mysore facility | Leased software park, minimal capex (~$2 mn), support medical and industrial growth | Next financial year |
| M&A | Several conversations in advanced stages; management hopes to close an LOI | This quarter (aspiration) |
| Order book breakup disclosure | May start providing order book breakup by industry | From next call |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | INR321 cr, +49.7% YoY, highest ever quarterly revenue |
| Revenue (9M FY24) | INR830 cr, +49.6% YoY, close to full-year FY23 revenue |
| EBITDA | INR29.4 cr, +42.7% YoY |
| EBITDA margin | 9.2%, down 45 bps YoY |
| EBITDA margin (9M FY24) | 8.8%, down 132 bps YoY due to planned SG&A investments |
| Profit after tax | INR18.4 cr, +222.6% YoY, driven by other income and volume growth |
| Profit after tax (9M FY24) | +100% YoY |
| Order backlog | INR2,294 cr, stable, ROI marginally higher than Q3 |
| Order intake | $41.8 mn |
| New awards | $10 mn, spread over three to four years, primarily defence |
| Inventory days | 137 days, marginally reduced QoQ; target 120 days short term, 90 days medium term |
| Free cash flow | -INR34 cr consumed in Q3; positive free cash flow expected in Q4 |
| IPO proceeds utilization | INR80 cr consumed towards working capital; external loans repaid |
| Capacity utilization | ~50% overall; Mysore near peak, Hyderabad still low |
| Defence revenue mix | 30–35% of overall revenue, expected to continue through the year |